Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 51.14

-2.0%

10:35 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: jayhawk969 who wrote (4254)	7/6/2001 9:15:29 AM
From: Biomaven	Read Replies (3) of 52153

Actually I think it's probably a good thing in the long run that the Administration's stem cell decision be made ahead of any FDA appointee. I think any new FDA head would have inevitably been drawn into the controversy and been damaged by it. It's hard to know how the stem cell decision is going to come out. I'm guessing there will be a "compromise" that prohibits money for cell stems derived from abortions or simply allows the existing lines to be used. Either way, the decision will have a way bigger impact on biotech stock prices in general than it should have. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next